

## Medibio acquires the US and Canadian patents covering the use of its Circadian Heart Rate technology to diagnose mental health disorders

---

**Sydney, Australia – 21 April 2015:** Medibio Ltd (**MEB** or the **Company**) is pleased to announce that it has entered into a binding agreement whereby it will acquire the U.S. and Canadian patents covering Circadian Heart Rate (“CHR”) technology for the diagnosis of depression and other mental health disorders. The patents also cover the use of CHR technology to determine the effectiveness of therapeutic interventions.

The acquisition of the U.S. patent 6,245,021 and Canadian patent 2,284,553 completes the consolidation of the suite of granted intellectual property that the Company has targeted to support the commercialization strategy of Medibio’s proprietary depression and mental health diagnostic technologies.

Under the acquisition agreement Medibio will acquire the patents from IFEM-CTAC Limited for US\$2.5 million with payment due in 3 years. At its sole discretion Medibio may elect to extend the payment period for an additional 2 years to a total of 5 years. IFEM-CTAC Limited, the patent owner, can elect to be paid in cash or Medibio shares at a price of 31<sup>#</sup> cents per share. Medibio can also, at its sole discretion, elect to make an early payment in which case IFEM-CTAC Limited must notify Medibio if it elects to take payment in cash or shares. Interest is payable at a rate of 8% pa semi-annually on the outstanding acquisition price.

***“We are delighted to have completed the acquisition of the U.S. and Canadian patents that cover Medibio’s CHR technology”,*** said Mr Kris Knauer the CEO of Medibio. ***“This IP assures our monopoly rights in the U.S., the largest medical diagnostic market in the world, where the cost burden of depression is estimated at \$US210 billion per annum.”***

The acquisition of the U.S. and Canadian patent rights completes an impressive list of achievements in recent months by the Company, which has seen the appointment of new management, a new Board and Advisory Board, a substantial corporate restructure, a \$2.6 million capital raise and the initiation of clinical validation trials at the Black Dog Institute in Sydney and Johns Hopkins University in Baltimore, USA.

|  |   |
|--|---|
| <b>Further Information:</b>  | Website: <a href="http://www.medibio.com.au">www.medibio.com.au</a>   |
| <b>Medibio Shareholder Enquiries to:</b><br>Kris Knauer<br>CEO and Director Medibio Limited<br><a href="mailto:kris.knauer@medibio.com.au">kris.knauer@medibio.com.au</a><br>T: +61 (0)411 885 979 | <b>Medibio Media Enquiries to:</b><br>Peter Taylor<br>NWR Communications<br><a href="mailto:Peter@nwrcommunications.com.au">Peter@nwrcommunications.com.au</a><br>T: +61 (0)412 036 231 |

*# Under the patent acquisition agreement IFEM-CTAC Limited can elect to be paid in Medibio shares with the share price the lower of A\$0.31 or US\$0.30 cents per share*

**About Medibio Limited**

Medibio (ASX: MEB), is a medical technology company developing a new objective test to assist in the diagnosis of depression, other mental health disorders and chronic stress. This tests utilise circadian heart rate variability. The technology is based on the scientific finding that circadian heart rate variability is a sensitive measure for depression and other mental health disorders and chronic stress. The technology consists of a heart monitor that sends ECG recordings wirelessly to the internet where proprietary algorithms analyse and delivers a quantifiable measure which can be used by a clinician to assist in diagnosis. The technology has the potential to be the first FDA-approved, objective, evidence based approach to the diagnosis of depression and other mental health disorders. The technology has already benefited from 10 years of laboratory research and Medibio is undertaking a number of pivotal studies to validate its clinical utility.